Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers

Cancer Letters

Volumn 235, Issue 2, 2006, Pages 272-280

  Surowiak, Paweł ^a,b,c   Materna, Verena ^a   Denkert, Carsten ^a   Kaplenko, Irina ^d   Spaczyński, Marek ^d   Dietel, Manfred ^a   Zabel, Maciej ^b,d   Lage, Hermann ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Chemotherapy; Cyclooxygenase 2; MDR1 P glycoprotein; Ovarian carcinoma

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROSTAGLANDIN E2;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CHEMISTRY; MORTALITY; OVARY TUMOR; PHYSIOLOGY;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; P-GLYCOPROTEIN;

EID: 33745018154     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.04.035     Document Type: Article

References (18)

1. Averette H.E., Hoskins W., Nguyen H.N., Boike G., Flessa H.C., Chmiel J.S., et al. National survey of ovarian carcinoma. 1. A patient care evaluation study of the Amercian College of Surgeons. Cancer 71 (1993) 1629-1638
2. McGuire III W.P., and Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer 89 (2003) 53-58
3. Lage H. ABC-transporters: implications on drug resistance form microorganisms to human cancer. Int. J. Antimicrob. Agents 22 (2003) 188-199
4. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. 21 (2001) 48-58
5. Materna V., Pleger J., Hoffmann U., and Lage H. RNA expression of MDR1/P-glyocprotein, DNA-topoisomerase, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol. Oncol. 94 (2004) 152-160
6. Gasparini G., Longo R., Sarmiento R., and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 4 (2003) 605-615
7. Denkert C., Winzer K.J., Muller B.M., Weichert W., Pest S., Kobel M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97 (2003) 2978-2987
8. Ristimäki A., Nieminen O., Saukkonen K., Hotakainen K., Nordling S., and Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 158 (2001) 849-853
9. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 160 (2002) 893-903
10. Mann J.R., and DuBois R.N. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 10 (2004) 145-152
11. Patel V.A., Dunn M.J., and Sorokin A. Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 227 (2002) 38915-38920
12. In: Sobin L.H., and Wittekind Ch. (Eds). UICC. TNM Classification of malignant tumors (1997), Wiley-Liss, New York
13. Shimizu Y., Kamoi S., Amada S., and Silverberg S.G. Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82 (1998) 893-901
14. Denkert C., Weichert W., Pest S., Koch I., Licht D., Kobel M., Hauptmann S., et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res. 64 (2004) 189-195
15. Remmele W., and Stenger H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8 (1987) 138-140
16. Yokoyama Y., Sato S., Fukushi Y., Sakamoto T., Futagami M., and Saito Y. Significance of multi-drug-resistant protein in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 25 (1999) 387-394
17. Denkert C., Kobel M., Berger S., Siegert A., Leclere A., Trefzer U., and Hauptmann S. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61 (2001) 303-308
18. Denkert C., Furstenberg A., Daniel P.T., Koch I., Kobel M., Weichert W., et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22 (2003) 8653-8661